POLYMORPHISMS OF α1-ANTITRYPSIN AND
INTERLEUKIN-6 GENES AND THE PROGRESSION
OF HEPATIC CIRRHOSIS IN PATIENTS WITH
A HEPATITIS C VIRUS INFECTION
Motawi T, Shaker OG, Hussein RM, Houssen M
*Corresponding Author: Rasha M. Hussein, Ph.D., Department of Biochemistry, Faculty of Pharmacy, Beni-Suef University,
Salah Salem Street, 62511, Beni-Suef, Egypt. Tel: +20-12-0013-6515. Fax: +20-82-2317-958. E-mail: rasha.hussein@
pharm.bsu.edu.eg
page: 35
|
|
REFERENCES
1. Breban R, Doss W, Esmat G, Elsayed M, Hellard M,
Ayscue P, et al. Towards realistic estimates of HCV
incidence in Egypt. J Viral Hepat. 2013; 20(4): 294-296.
2. Zucker S. Whomsoever ignores the natural history
of the hepatitis C virus is doomed to treat it. Gastroenterology.
2002; 122(2): 578-579.
3. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression
in chronic hepatitis C: Modifiable and nonmodifiable
factors. Gastroenterology. 2008; 134(6):
1699-1714.
4. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV,
Urban TJ, et al. Genetic variation in IL28B predicts
hepatitis C treatment-induced viral clearance. Nature.
2009; 461(7262): 399-401.
5. Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S,
Fontanini E, et al. Interleukin 6 promoter polymorphisms
influence the outcome of chronic hepatitis C.
Immunogenetics. 2011; 63(1): 33-41.
6. Giannitrapani L, Soresi M, Giacalone A, Campagna
ME, Marasà M, Cervello M, et al. IL-6−174G/C
polymorphism and IL-6 serum levels in patients with
liver cirrhosis and hepatocellular carcinoma. OMICS.
2011; 15(3): 183-186.
7. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V,
Yudkin JS, Humphries S, et al. The effect of novel
poly-morphisms in the interleukin-6 (IL-6) gene on
IL-6 transcription and plasma IL-6 levels, and an
association with systemic-onset juvenile chronic arthritis.
J Clin Invest. 1998; 102(7): 1369-1376.
8. Falleti E, Fabris C, Vandelli C, Colletta C, Cussigh A,
Smirne C, et al. Genetic polymorphisms of interleukin-
6 modulate fibrosis progression in mild chronic
hepatitis C. Hum Immunol. 2010; 71(10): 999-1004.
9. Crystal RG, Brantly ML, Hubbard RC, Curiel DT,
Holmes MD. The α1-antitrypsin gene and its mutations.
Clinical consequences and strategies for therapy.
Chest. 1989; 95(1): 196-208.
10. Norman MR, Mowat AP, Hutchison D. Molecular
basis, clinical consequences and diagnosis of α-1
anti-trypsin deficiency. Ann Clin Biochem. 1997;
34(Pt 3): 230-246.
11. Canva V, Piotte S, Aubert J-P, Porchet N, Lecomte-
Houcke M, Huet G, et al. Heterozygous M3Mmalton
α1-antitrypsin deficiency associated with end-stage
liver disease: Case report and review. Clin Chem.
2001; 47(8): 1490-1496.
12. Luisetti M, Seersholm N. α1-Antitrypsin deficiency
1: Epidemiology of α1-antitrypsin deficiency. Thorax.
2004; 59(2): 164-169.
13. Fregonese L, Stolk J. Hereditary α1-antitrypsin deficiency
and its clinical consequences. Orphanet J Rare
Dis. 2008; 3: 16. doi: 10.1186/1750-1172-3-16.
14. Perlmutter DH, May LT, Sehgal PB. Interferon beta
2/interleukin 6 modulates synthesis of α1-antitrypsin
in human mononuclear phagocytes and in human
hepatoma cells. J Clin Invest. 1989; 84(1): 138-144
15. Child CG, Turcotte J. Surgery and portal hypertension.
Major Probl Clin Surg. 1964; 1: 1-85.
16. Pugh R, Murray Lyon I, Dawson J, Pietroni M, Williams
R. Transection of the oesophagus for bleeding
oesophageal varices. Br J Surg. 1973; 60(8): 646-649.
17. Henry R, Chiamori M, Golub O, Berkman S. Revised
spectrophotometric methods for the determination of
glutamate oxaloacetic transaminase, glutamic pyruvate
transaminase and lactic acid dehydrogenase. Am
J Clin Pathol. 1960; 34: 381-387.
18. Amador E, Wacker WE. Serum glutamic-oxaloacetic
transaminase activity. A new modification and an
analytical assessment of current assay technics. Clin
Chem. 1962; 8(4): 343-350.
19. Bretaudiere J, Vassault A, Amsellem L, Pourci M,
Thieu-Phung H, Bailly M. Criteria for establishing a
standardized method for determining alkaline phosphatase
activity in human serum. Clin Chem. 1977;
23(12): 2263-2274.
20. Landis JB, Pardue HL. Kinetics of the reactions of
unconjugated and conjugated bilirubins with p-diazobenzenesulfonic
acid. Clin Chem. 1978; 24(10):
1690-1699.
21. Hirai H. Alpha fetoprotein. In: Chu TM, Ed. Biochemical
Markers for Cancer. New York, NY, USA:
Marcel Dekker Inc. 1982: 23-59.
22. Glasel J. Validity of nucleic acid purities monitored
by 260nm/280nm absorbance ratios. Biotechniques.
1995; 18(1): 62-63.
23. Mohamoud YA, Mumtaz GR, Riome S, Miller D,
Abu-Raddad LJ. The epidemiology of hepatitis C virus
in Egypt: A systematic review and data synthesis.
BMC Infect Dis. 2013; 13(1): 288.
24. Guerra J, Garenne M, Mohamed M, Fontanet A. HCV
burden of infection in Egypt: Results from a nationwide
survey. J Viral Hepat. 2012; 19(8): 560-567.
25. Meenagh A, Williams F, Ross OA, Patterson C, Gorodezky
C, Hammond M, et al. Frequency of cytokine
polymorphisms in populations from western Europe,
Africa, Asia, the Middle East and South America.
Hum Immunol. 2002; 63(11): 1055-1061.
26. Barrett S, Collins M, Kenny C, Ryan E, Keane C,
Crowe J. Polymorphisms in tumour necrosis factor
α, transforming growth factor β, interleukin 10, interleukin
6, interferon γ, and outcome of hepatitis C
virus infection. J Med Virol. 2003; 71(2): 212-218.
27. Pereira FA, Silva NNPd, Rodart IF, Carmo TMAd,
Lemaire DC, Reis MGd. Association of TGF-beta1
codon 25 (G915C) polymorphism with hepatitis C
virus infection. J Med Virol. 2008; 80(1): 58-64.
28. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z,
Koniaris LG. Paradoxical effects of short and long
term interleukin 6 exposure on liver injury and repair.
Hepatology. 2006; 43(3): 474-484.
29. Shaker OG, Sadik NA. Polymorphisms in interleukin
10 and interleukin 28B genes in Egyptian patients
with chronic hepatitis C virus genotype 4 and their
effect on the response to pegylated interferon/ribavirin
therapy. J Gastroenterol Hepatol. 2012; 27(12):
1842-1849.
30. Shalaby SM, Radwan MI, Abdelazim S, Nafee AM.
Interleukin-4 polymorphisms and response to combination
therapy in Egyptian chronic hepatitis C patients.
Cell Immunol. 2012; 276(1): 110-113.
31. Abdel-Hady H, El-Naggar M, El-Nady G, Badr R,
El-Daker M. Genetic polymorphisms of IL-6-174
and IL-10-1082 in full term neonates with late onset
blood stream infections. J Pediatr Infect Dis. 2009;
4(4): 357-365.
32. Helaly MA-H, Hatata E-SZ, Abu-Elmagd M, Ibrahem
EF, Alsaid A, El-Aal IAA, et al. Association of IL-10
and IL-6 gene polymorphisms with type 2 diabetes
mellitus among Egyptian patients. Eur J Gen Med.
2013; 10(3): 158-162.
33. Zekri A, Ashour MS, Hassan A, HM AE-D, El-Shehaby
A, Abu-Shady MA. Cytokine profile in Egyptian
hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;
11(42): 6624-6630.
34. Settin A, El-Bendary M, Abo-Al-Kassem R, El Baz
R. Molecular analysis of A1AT (S and Z) and HFE
(C282Y and H63D) gene mutations in Egyptian cases
with HCV liver cirrhosis. J Gastrointestin Liver Dis.
2006; 15(2): 131-135
35. Gharib AF, Karam RA, Pasha HF, Radwan MI, Elsawy
WH. Polymorphisms of hemochromatosis, and
α-1 antitrypsin genes in Egyptian HCV patients with
and without hepatocellular carcinoma. Gene. 2011;
489(2): 98-102.
36. de Serres FJ, Blanco I. Prevalence of α1-antitrypsin
deficiency alleles PI* S and PI* Z worldwide and
effective screening for each of the five phenotypic
classes PI* MS, PI* MZ, PI* SS, PI* SZ, and PI*
ZZ: a comprehensive review. Ther Adv Respir Dis.
2012; 6(5): 277-295.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
